Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Guggenheim has earned $172 million from advising Pfizer on nearly $400 billion in acquisitions since 2011. Pfizer’s stock ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
Former Pfizer Inc. executives Ian Read and Frank D’Amelio have decided “not to be involved” in Starboard Value’s activist ...
The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.
Presentations highlight momentum of Pfizer’s portfolio of infectious disease prevention and treatment options NEW YORK, October 08, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present ...
For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback